Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...